Sonnet BioTherapeutics (SONN) announced that the United States Patent and Trademark Office has issued a Notice of Allowance to the Company for a second patent in the IL-18 variant protein field which discloses the amino acid sequence of its variant human IL-18BPR protein. The allowed patent claims cover variant human IL-18 proteins, including but not limited to hIL-18 proteins having amino acid substitutions at the following positions: Y1W, Y1K, M51Y, M51S, M60W, S105E, and D110Y, relative to human wildtype IL-18. Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the allowed patent.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics Highlights Promising SON-1010 Data
- Sonnet BioTherapeutics presents data on SON-1010
- Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform
- Sonnet announces ADC platform available for drug discovery partnerships
- Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments
Questions or Comments about the article? Write to editor@tipranks.com